(Q35039491)

5 August 2017

1 reference

title

Aromatase inhibitors in breast cancer: an update (English)

1 reference

5 August 2017

Diana E Lake

1

1 reference

5 August 2017

Clifford Hudis

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

490-498

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Anti-aromatase agents in the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900606

10.1177/107327480200900606

21 January 2018

Identifiers

DOI

0 references

1 reference